Thus, it is concluded that ARHGEF9 is a glioma suppressor gene that acts through the PI3K/AKT/mTOR pathway, which reveals part of the mechanism between peptides and gliomas and provides a new potential therapeutic target and a prognostic biomarker for patients. Here, MTOR is linked to central nervous system cancer.